Glycemic variability and diabetes complications: Does it matter? Simply put, there are better glycemic markers!

Diabetes Care

Volumn 38, Issue 8, 2015, Pages 1615-1621

  Bergenstal, Richard M ^a  

^a INTERNATIONAL DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; REACTIVE OXYGEN METABOLITE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ACUTE HEART INFARCTION; AMPUTATION; ARTICLE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; END STAGE RENAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC VARIABILITY; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; METABOLISM; MICROVASCULATURE; PHYSIOLOGY;

BIOMARKERS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; MICROVESSELS;

EID: 84960880568     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0099     Document Type: Article

References (37)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
3. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
4. Orchard TJ, Nathan DM, Zinman B, et al.; Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45-53.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
6. Wentholt IME, Kulik W, Michels RPJ, Hoekstra JBL, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008;51: 183-190.
7. Hirsch IB, Brownlee M. Beyond hemoglobin A1cdneed for additional markers of risk for diabetic microvascular complications. JAMA 2010;303:2291-2292.
8. Mazze RS, Strock E, Wesley D, et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther 2008;10:149- 159.
9. Borg R, Kuenen JC, Carstensen B, et al.; ADAG Study Group. HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: The A1C-Derived Average Glucose (ADAG) study. Diabetologia 2011;54:69-72.
10. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial. Diabetes Care 2009;32:381-386.
11. Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: A reanalysis of the HEART2D study. Diabetes Care 2011;34:855-857.
12. Monnier L, Colette C. Glycemic variability: can we bridge the divide between controversies? Diabetes Care 2011;34:1058-1059.
13. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006;29:1486-1490.
14. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trialdrevisited. Diabetes 2008; 57:995-1001.
15. Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH. Rate of hypoglycemia in insulintreated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther 2012;14:1008-1012.
16. Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: A randomized, controlled, crossover trial. J Clin Endocrinol Metab 2012;97: 3504-3514.
17. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009;11(Suppl. 1):S55-S67.
18. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013;15: 198-211.
19. Matthaei S. Assessing the value of the Ambulatory Glucose Profile in clinical practice. Br J Diabetes Vasc Dis 2014;14:148-152.
20. Matthaei S, DeAlaiz RA, Bosi E, Evans M, Geelhoed-Duijvestijn N, Joubert M. Consensus recommendations for the use of Ambulatory Glucose Profile in clinical practice. Br J Diabetes Vasc Dis 2014;14:153-157.
21. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644-655.
22. Service FJ. Glucose variability. Diabetes 2013;62:1398-1404.
23. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005;7:253- 263.
24. Nathan DM, Zinman B, Cleary PA, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983-2005). Arch Intern Med 2009;169:1307-1316.
25. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013;368:1613-1624.
26. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370: 1514-1523.
27. Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012;35: 1814-1816.
28. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45: 937-948.
29. Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med 2014; 174:1116-1124.
30. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013;347:f4533.
31. Kong AP, Yang X, Luk A, et al. Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: The Hong Kong diabetes registry. Diabetes Care 2014;37:1024-1031.
32. Yaffe K, Falvey CM, Hamilton N, et al.; Health ABC Study. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med 2013;173:1300-1306.
33. Willis WD, Diago-Cabezudo JI, Madec-Hily A, Aslam A. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey. Expert Rev Pharmacoecon Outcomes Res 2013;13: 123-130.
34. Cryer PE. Glycemic goals in diabetes: Tradeoff between glycemic control and iatrogenic hypoglycemia. Diabetes 2014;63:2188-2195.
35. Rodbard D. Evaluating quality of glycemic control: graphical displays of hypo- And hyperglycemia, time in target range, and mean glucose. J Diabetes Sci Tech 2015;9:56-62.
36. Vigersky RA. Escaping the hemoglobin A1ccentric world in evaluating diabetes mellitus interventions. J Diabetes Sci Technol. 19 February 2015 [Epub ahead of print].
37. The FLAT-SUGAR Trial Investigators. Design of FLAT-SUGAR: randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes. Diabetes Care 2015; 38:1558-1566.